PTC Therapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • PTC Therapeutics's estimated annual revenue is currently $492.2M per year.(i)
  • PTC Therapeutics's estimated revenue per employee is $327,498
  • PTC Therapeutics's total funding is $568M.
  • PTC Therapeutics's current valuation is $3.1B. (January 2022)

Employee Data

  • PTC Therapeutics has 1503 Employees.(i)
  • PTC Therapeutics grew their employee count by -15% last year.

PTC Therapeutics's People

Sr. VP, Pharmacology and BiomarkersReveal Email/Phone
CFOReveal Email/Phone
Chief Staff to the CEOReveal Email/Phone
Chief Staff to the CFOReveal Email/Phone
Chief Staff to the Chief Business OfficerReveal Email/Phone
CEOReveal Email/Phone
Chief Staff to the CIOReveal Email/Phone
Chief Staff and Commercial Operations EMEAReveal Email/Phone
CEOReveal Email/Phone
Executive Director, Corporate AccountingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is PTC Therapeutics?

PTC Therapeutics, Inc. discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC's compounds modulate gene expression by selectively binding to either RNA targets or proteins that interact with RNA. This approach has progressed the Company's drug discovery programs rapidly from targets to lead optimization. PTC's pipeline includes programs in infectious diseases, oncology, inflammation, and genetic disorders.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





PTC Therapeutics News

2022-04-20 - PTC Therapeutics to Host Conference Call to Discuss First ...

SOUTH PLAINFIELD, N.J., April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference...

2022-04-19 - PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected to Announce Quarterly Sales of $145.24 Million. Posted by admin on Apr 18th, 2022.

2022-04-17 - PTC Therapeutics Provides Update on EMA Regulatory ...

About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and...

2021-10-25 - PTC Therapeutics : Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil

SOUTH PLAINFIELD, N.J., Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include ...

2021-10-11 - PTC Therapeutics : Tegsedi® Receives Innovative Drug Category Pricing in Brazil

SOUTH PLAINFIELD, N.J., Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil. Categor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding